Inhibition of murine melanoma growth by granulocyte-macrophage colony stimulating factor gene transfection is not haplotype specific

Melanoma Research

Volumn 8, Issue 3, 1998, Pages 245-254

  Botella, R ^a   Sarradet, M D ^b,c   Potter, L E ^b,c   Lawley, M ^b,c   Galloway, T H ^b,c   Ansel, J C ^b,c   Armstrong, C A ^b,c  

^a INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cytokine; GM CSF; Haplotype; Immunotherapy; Melanoma

Indexed keywords

CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ANIMAL CELL; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CELL INFILTRATION; CYTOKINE RELEASE; FEMALE; GENETIC TRANSFECTION; HAPLOTYPE; HISTOPATHOLOGY; IMMUNOMODULATION; INOCULATION; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD86; CANCER VACCINES; CELL DIVISION; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; HAPLOTYPES; IMMUNOHISTOCHEMISTRY; MELANOMA; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C3H; SPECIFIC PATHOGEN-FREE ORGANISMS; SURVIVAL RATE; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0031863566     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199806000-00007     Document Type: Article

References (42)

1. Mukherji B, Chakraborty N. Immunobiology and immunotherapy of melanoma. Curr Opin Oncol 1995; 7: 175-184.
2. Ettinghousen SE, Rosenberg SA. Immunotherapy and gene therapy of cancer. Adv Surg 1995; 28: 223-254.
3. Maio M. Immunology of Human Melanoma: Tumor-Host Interaction and Immunotherapy. Amsterdam: IOS Press, 1996.
4. Berns AJM, Clift S, Cohen LK, Donehower RC, Dranoff G, Hauda KM, Jaffee EM, Lazenby AJ, Levitsky HI, Marshall FF, Mulligan RC, Nelson WG, Owen AG, Pardoll DM, Parry G, Partin AH, Piantodosi S, Simons JW, Zabora JR. Phase I study of non-replicating autologous tumor cell injections using cells prepared with or without GM-CSF gene transduction in patients with metastatic renal cell carcinoma. Hum Gene Ther 1995; 6: 347-368.
5. Schadendorf D, Czarnetzki BM, Wittig B. Interleukin-7, interleukin 12, and GM-CSF gene transfer in patients with metastatic melanoma. J Mol Med 1995; 73: 473-477.
6. Ellem KAO, O'Rourke MGE, Johnson GR, Parry G, Misko IS, Schmidt CW, Parsons PG, Burrows SR, Cross S, Fell A, Li CL, Bell JR, Dubois PJ, Moss DJ, Good MF, Kilso A, Cohen LK, Dranoff G, Mulligan RC. A case report: immune responses and clinical course of the first human use of granulocyte/macrophage-colony-stimulating-factor-transduced autologous melanoma cells for immunotherapy. Cancer Immunol Immunother 1997; 44: 10-20.
7. Armstrong CA, Botella R, Galloway TH, Murray NM, Kramp JM, Song IS, Ansel JC. Antitumor effects of granulocyte-macrophage colony-stimulating factor production by melanoma cells. Cancer Res 1996; 56: 2191-2198.
8. Dranoff G, Jaffe E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-3543.
9. Abe J, Wakimoto H, Yoshida Y, Aoyagi M, Hirakawa K, Hamada H. Antitumor effect induced by GM-CSF gene-modified tumor vaccination: comparison of adenovirus- and retrovirus-mediated genetic transduction. J Cancer Res Clin Oncol 1995; 121: 587-592.
10. Qin HX, Chatterjee SK. Construction of recombinant vaccinia virus expressing GM-CSF and its use as tumor vaccine. Gene Ther 1996; 3: 59-66.
11. Sampson JH, Archer GE, Ashley DM, Fuchs HE, Hale LP, Dranoff G, Bigner DD. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the 'immunologically privileged' central nervous system. Proc Natl Acad Sci USA 1996; 93: 10399-10404.
12. Kripke ML. Speculations on the role of ultraviolet radiation in the development of malignant melanoma. J Natl Cancer Inst 1979; 63: 541-548.
13. Gough NM, Metcalf D, Gough J, Grail D, Dunn AR. Structure and expression of the mRNA for murine granulocyte-macrophage colony stimulating factor. EMBO J 1985; 4: 645-653.
14. Cepko CL, Roberts BE, Mulligan RC. Construction and applications of a highly transmissible murine retrovirus shuttle vector. Cell 1984; 37: 1053-1062.
15. Armstrong CA, Murray N, Kennedy M, Kopula SV, Tara D, Ansel JC. Melanoma-derived interleukin 6 inhibits in vivo melanoma growth. J Invest Dermatol 1994; 102: 278-284.
16. London L, McKearn JP. Activation and growth of colony-stimulating factor-dependent cell lines is cell cycle stage dependent. J Exp Med 1987; 166: 1419-1435.
17. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 1989; 24: 148-154.
18. Vieweg J, Rosenthal FM, Bannerji R, Heston WDW, Fair WR, Gansbacher B, Gilboa E. Immunotherapy of prostate cancer in the dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res 1994; 54: 1760-1765.
19. Golumbek PT, Azhari R, Jaffee EM, Levitsky HI, Lazenby A, Leong K, Pardoll DM. Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design. Cancer Res 1993; 53: 5841-5844.
20. Levitzky HI, Lazenby A, Hayashi RJ, Pardoll DM. In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J Exp Med 1994; 179: 1215-1224.
21. Levitsky HI, Montgomery J, Ahmadzadeh M, Staveley-O'Carroll K, Guarnieri F, Longo DL, Kwak LW. Immunization with GM-CSF-transduced, but not B7-1-transduced lymphoma cells primes idiotype specific T cells and generates potent systemic anti-tumor immunity. J Immunol 1996; 156: 3858-3865.
22. Saito S, Bannerji R, Gansbacher B, Rosenthal FM, Romanenko P, Heston WDW, Fair WR, Gilboa E. Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines. Cancer Res 1994; 54: 3516-3520.
23. Townsend SE, Allison JP. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 1993; 259: 368-370.
24. Li Y, Hellstrom KE, Newby SA, Chen L. Costimulation by CD28 and B7-1 induces immunity against poorly immunogenic tumors. J Exp Med 1996; 183: 639-644.
25. Bonnekoh B, Breenhalgh DA, Bundman DS, Kosai K-I, Chen S-H, Finegold MJ, Krieg T, Woo SLC, Roop DR. Adenoviral-mediated herpes simplex virus-thymidine kinase gene transfer in vivo for treatment of experimental human melanoma. J Invest Dermatol 1996; 106: 1163-1168.
26. d mice that reject syngeneic tumors. J Immunol 1996; 157: 3550-3558.
27. Raj NBK, Cheung SC, Rosztoczy I, Pitha PM. Mouse genotype affects inducible expression of cytokine genes. J Immunol 1992; 148: 1934-1940.
28. Taniguchi T. Regulation of cytokine gene expression. Annu Rev Immunol 1988; 6: 439.
29. DeMaeyer-Guignard J, Dandoy F, Bailey DW, DcMaeyer E. Interferon structural genes do not participate in quantitative regulation of interferon production by If loci as shown in C57BL/6 mice that are congenic with BALB/c mice at the α interferon gene cluster. J Virol 1986; 58: 743.
30. Dinarello CA. Interleukin-1 and its biologically related cytokines. Adv Immunol 1989; 44: 153-205.
31. Khan SG, Mohan RR, Katiyar SK, Wood GS, Bickers DR, Mukhtar H, Agarwal R. Mutations in ras oncogenes: rare events in ultraviolet B radiation-induced mouse skin tumorigenesis. Mol Carcinogenesis 1996; 15: 96-103.
32. Noonan FP, De Fabo EC. Ultraviolet-B dose-response curves for local and systemic immunosuppression are identical. Photochem Photobiol 1990; 52: 801-810.
33. Noonan FP, Hoffman HA. Susceptibility to immunosuppression by ultraviolet B radiation in the mouse. Immunogenetics 1994; 39: 29-39.
34. Streilein JW, Bergstresser PR. Genetic basis of ultraviolet B effects on contact hypersensitivity. Immunogenetics 1988; 27: 252-258.
35. Yoshikawa T, Streilein JW. Genetic basis of the effects of ultraviolet light B on cutaneous immunity. Evidence that polymorphism at Tnfa and Lps loci governs susceptibility. Immunogenetics 1990; 32: 398-405.
36. Donawho C, Kripke ML. Immunogenicity and cross-reactivity of syngeneic murine melanomas. Cancer Comm 1993; 2: 101-107.
37. Talmadge JE, Fidler IJ. Enhanced metastatic potential of tumor cells harvested from spontaneous metastases of heterogeneous murine tumors. J Natl Cancer Inst 1982; 69: 975-980.
38. Schackert G, Fidler IJ. Development of in vivo models for studies of brain metastasis. Int J Cancer 1988; 41: 589-594.
39. Cegon JS, Lieschke GJ. Granulocyte-macrophage colony-stimulating factor for cancer treatment. Oncology 1994; 51: 177-188.
40. Chachoua A, Oratz R, Liebes L, Alter RS, Felice A, Peace D, Vilcek J, Blum RH. Phase Ib trial of granulocyte-macrophage colony-stimulating factor combined with murine monoclonal antibody R24 in patients with metastatic melanoma. J Immunother 1994; 16: 132-141.
41. Jager K, Ringhoffer M, Dienes HP, Arand M, Karbach J, Jager D, Ilsemann C, Hagedorn M, Oesch F, Knuth A. Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int J Cancer 1996; 67: 54-62.
42. Sternas K, Janil JE, Duffey PL, Gocke C, Reynolds CW, Wittes RE, Kwak LW. Early results of a clinical trial of therapeutic vaccination with Ig idiotype antigen for de novo follicular lymphoma. Blood 1996; 88: 672a.